About Us
Chairwoman of the Board, Executive Director: Ms. Theresa Tse
-
- Chairwoman of the Board, Executive Director: Ms. Theresa Tse
- Since 2015, she has served as Chairwoman of the Board of Sino Biopharmaceutical Limited and Vice Chairwoman of Chia Tai Pharmaceutical Group. In 2017, she served as the Director of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Vice Chairwoman of Beijing Tide Pharmaceutical Co., Ltd. Ms. Theresa Tse holds a Bachelor of Science Degree in Economics from the Wharton School of the University of Pennsylvania. She has been listed on Forbes' "Top 100 Businesswomen in China" list eight times and was selected for Bloomberg Businessweek's "Bloomberg 50" in 2024.
Since taking office, Theresa Tse has led the company's strategic transformation from generic drugs to innovative drugs, driving business upgrades by increasing R&D investment, building an international R&D platform, and executing a series of capital operations. Theresa Tse actively promotes resource integration and international cooperation. Collaborative projects with multinational pharmaceutical companies such as Boehringer Ingelheim, Shionogi, and Sanofi have advanced rapidly. She has also led several mergers and acquisitions, including the acquisitions of HOB Biotech, LaNova Medicines, and Hygieia Pharmaceuticals, significantly enhancing the company's innovative R&D capabilities and global competitiveness. In recent years, the company's R&D investment as a percentage of revenue has continued to increase. Its R&D pipeline has become one of the largest globally, establishing the company as a major force in global pharmaceutical R&D. Adhering to the philosophy of "Healthy Technology, Warming More Lives", the company focuses on four core therapeutic areas: neoplasm, liver disease, respiratory, and surgery/analgesia, and is dedicated to improving patients' quality of life. As its innovative products enter a period of intensive harvest, Sino Biopharmaceutical Limited will continue to contribute more breakthrough treatment options for patients worldwide.
While adhering to innovative R&D, Theresa Tse leads Sino Biopharmaceutical Limited and its member companies in actively undertaking social responsibilities and participating in various public welfare and charitable activities. She upholds the Charoen Pokphand Group (CP Group)'s business tenet of "Benefiting the Country, the People, and the Enterprise". She also promotes the group's establishment of an Environmental, Social, and Governance (ESG) system centered on "CARE" (Cure, Accessibility, Relationship, Environment) and systematically implements management practices such as carbon neutrality pathway planning, improving medicine accessibility, employee stock incentives, and building a responsible supply chain. In 2025, the Group was the first in China's pharmaceutical industry to release the "Carbon Neutrality Goals and Pathway Plan". It has ranked in the top 6% of global pharmaceutical companies in the S&P Global Corporate Sustainability Assessment (CSA) for two consecutive years and was the only pharmaceutical company selected for the main list of Forbes China's "2024-2025 Sustainable Development Industrial Enterprises".
Under the leadership of Theresa Tse, Sino Biopharmaceutical Limited was included as a constituent stock of the Hang Seng Index in 2018 and became a constituent of the Hang Seng SCHK Biotech 50 Index in 2020. The company has been ranked among the "Top 50 Global Pharmaceutical Companies" by the authoritative US magazine Pharm Exec for seven consecutive years and has been named one of Forbes Asia's "Asia's Fab 50" for three consecutive years. Core enterprises CTTQ Pharma and Beijing Tide Pharmaceutical have been listed on authoritative rankings such as the "Top 100 Chinese Pharmaceutical Companies" and "China's Best Industrial Enterprises in Pharmaceutical R&D Pipelines" for many consecutive years.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Xinhua News Agency | Sino Biopharm Reports 140.2% YoY Growth in H1 2025 Net Profit Attributable to Owners of the Parent 2025.08
Xinhua Finance, Nanjing, August 18 (Reporter: Zhu Cheng) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively.View > -
Ta Kung Pao | Net Profit Doubles with 27.2% Surge in Innovative Product Revenue - Sino Biopharm Announces 2025 Interim Results 2025.08
Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharm (01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.View > -
Sino Biopharm 2024 Full-Year Results Announcement: Double-Digit Growth in Both Revenue and Net Profit, Innovative Product Revenue Exceeds 12 Billion, a New High 2025.03
On March 20, Sino Biopharm (HK.01177) released its 2024 annual results report, delivering an impressive "double-digit growth" across two key metrics: full-year revenue for 2024 reached RMB 28.87 billion, a year-on-year increase of 10.2%, hitting a record high; adjusted net profit attributable to owners of the parent company reached RMB 3.46 billion, a year-on-year increase of 33.5%.View > -
.jpg)
Listed for the Seventh Time, Ms. Theresa Tse Selected as one of "Forbes China's Outstanding Businesswomen" 2025.03
Recently, the 2025 "Forbes China's Top 100 Outstanding Businesswomen" list was officially released. Miss Theresa Tse, Chairwoman of the Board of Sino Biopharm (1177.HK), was named to the list, marking the seventh time she has been honored with this award.View > -
.jpg)
Ms. Theresa Tse Attended the 25th CIFIT: China's Pharmaceutical Innovation Momentum is Blooming, and Called for Mutually Beneficial Sino-Foreign Cooperation 2025.09
On September 8, the 25th China International Fair for Investment & Trade (CIFIT) grandly opened in Xiamen.View > -
Blockbuster Deal! $500 Million Acquisition of LaNova Medicines to Further Accelerate Sino Biopharm's Innovation and Internationalization 2025.07
On July 15, Sino Biopharm (1177.HK) made a major announcement that it will acquire 100% of LaNova Medicines Ltd. for a net consideration of approximately US$500 million.View > -
Sino Biopharm Held Briefing on LaNova Medicines Acquisition and Detailed Potential Assets of Four Major Platforms 2025.07
On the morning of July 17, Sino Biopharm, the parent company of Chia Tai Tianqing, held a briefing on the wholly-owned acquisition of LaNova Medicines.View > -
Sino Biopharm Reports Strong H1 Results: Net Profit Doubles, Innovation Drives Record Revenue of RMB 17.57 Billion 2025.08
On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.View >